Anne Jouret-Mourin

Anne Jouret-Mourin

Auto-generated profile, based on publicly available information

Anne Jouret-Mourin

Anatomopathology Department, IPG - Institut de Pathologie et de Genetique, Gosselies, Belgium

Research Focus & Metrics

Academic Career Length

9Years (2018-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 October 2020 in Clinical Cancer Research
Verified
Journal Article
Closed access
PDF file
CSCarine El Sissy
Carine El Sissy
AKAmos Kirilovsky
Amos Kirilovsky
MEMarc Van Den Eynde
Marc Van Den Eynde
AMAna-Maria Mușină
Ana-Maria Mușină
MAMaria-Gabriela Anitei
Maria-Gabriela Anitei
FPFranck Pagès
Franck Pagès
Purpose: No biomarker to personalize treatment in locally advanced rectal cancer (LARC) is currently available. We assessed in LARC whether a diagnostic biopsy-adapted immunoscore (ISB) could predict response to neoadjuvant treatment (nT) and better define patients eligible to an organ preservation strategy (“Watch-and-Wait”). Experimental Design: Biopsies from two independent cohorts (n1 = 131, n2 = 118) of patients with LARC treated with nT followed by radical surgery were immunostained for CD3+ and CD8+ T cells and quantified by digital pathology to determine ISB. The expression of immune-related genes post-nT was investigated (n = 64 patients). Results were correlated with response to nT and disease-free survival (DFS). The ISB prognostic performance was further assessed in a multicentric cohort (n = 73 patients) treated by Watch-and-Wait. Results: ISB positively correlated with the degree of histologic response (P < 0.001) and gene expression levels for Th1 orientation and cytotoxic immune response, post-nT (P = 0.006). ISB high identified patients at lower risk of relapse or death compared with ISB low [HR, 0.21; 95% confidence interval (CI), 0.06–0.78; P = 0.009]. Prognostic performance of ISB for DFS was confirmed in a validation cohort. ISB was an independent parameter, more informative than pre- (P < 0.001) and post-nT (P < 0.05) imaging to predict DFS. ISB combined with imaging post-nT discriminated very good responders that could benefit from organ preservation strategy. In the “Watch-and-Wait” cohort (n = 73), no relapse was observed in patients with ISB high (23.3%). Conclusions: ISB predicts response to nT and survival in patients with LARC treated by surgery. Its usefulness in the selection of patients eligible for a Watch-and-Wait strategy is strongly suggested.


7 May 2018 in Acta Chirurgica Belgica
Verified
Journal Article
Closed access
EUEwelina Uscilowska
Ewelina Uscilowska
NONora Abbes Orabi
Nora Abbes Orabi
DLDaniel Léonard
Daniel Léonard
AMAnne Mourin-Jouret
Anne Mourin-Jouret
LLLouis Libbrecht
Louis Libbrecht
AKAlex Kartheuser
Alex Kartheuser
Introduction: Lipomas are the most common benign mesenchymal tumors which can be found in any part of the body. Nevertheless, their etiology and pathogenesis remain unknown. It is hypothesized that some of these lesions could result from an acute or chronic trauma. Patients and methods: We report a case of a 54-year-old man presenting a perineal lipoma which volume grew rapidly after he fell on his buttock, in the context of inaugural epileptic seizure. Pelvic MRI showed a voluminous fatty mass, measuring 6.6 × 5 × 9 cm without any signs of local invasion. Furthermore, we review the latest research on lipomas originating from traumatic lesion. Results: The mass was completely excised in one block under general anesthaesia, using an elliptical incision and a deep dissection. We did not close the skin incision in view of the cutaneous defect. Post-operative recovery was uneventful and the patient was discharged from hospital two days after the operation. Histopathology indicated a reorganised lipoma with no evidence of malignancy. Conclusion: Perineal lipomas are extremely rare, pathological examination of imaging guided biopsies are needed to exclude malignancy especially a well-differentiated liposarcoma. MRI remains the first option and radical surgical excision is the gold standard treatment.

2 November 2018 in Acta Chirurgica Belgica
Verified
Journal Article
Closed access
JFJ. Frezin
J. Frezin
MKM. Komuta
M. Komuta
FZF. Zech
F. Zech
LAL. Annet
L. Annet
YHY. Horsmans
Y. Horsmans
CHC. Hubert
C. Hubert
Background: Mucin-producing hepatic cystic neoplasms (MHCN) are uncommon and potentially malignant. Methods: Nine MHCN were encountered in our centre for over 32 years. Patients’ clinical, biological, radiological and pathological features were reviewed. Lesions were classified into Mucinous Cystic Neoplasms (MCN) and Intraductal Papillary Neoplasms of the Bile duct (IPNB) (WHO 2010 classification). Results: Five MCN and 4 IPNB were reviewed. Serum and intracystic tumour markers were insufficient to diagnose malignancy. Complications were encountered in five out of nine patients (56%), mean symptom duration was 26 months (range: 1–132). Three patients were mismanaged pre-referral. Radiological features enabled preoperative diagnosis in eight out of nine patients (89%). Greater tumour size, unilocular lesion and mural nodularity indicated malignancy. Radical tumour excision was achieved in eight patients. One IPNB patient was misdiagnosed and underwent unroofing. For 103 months median follow-up, five out of six patients with benign tumours were alive and disease-free, whereas the misdiagnosed IPNB recurred with fatal malignant transformation seven years later. Among the three patients with malignancies (median follow-up: 77 months), two IPNB died, one from cancer recurrence and one from unrelated causes, whereas the malignant MCN was alive and disease-free. Conclusions: Appropriate MHCN diagnosis is crucial, yet it is often misdiagnosed and mismanaged. The prognosis after complete excision is favourable

31 March 2023
Verified
Other
Open access
CSCarine El Sissy
Carine El Sissy
AKAmos Kirilovsky
Amos Kirilovsky
MEMarc Van Den Eynde
Marc Van Den Eynde
AMAna-Maria Mușină
Ana-Maria Mușină
MAMaria-Gabriela Anitei
Maria-Gabriela Anitei
FPFranck Pagès
Franck Pagès

31 March 2023
Verified
Other
Open access
CSCarine El Sissy
Carine El Sissy
AKAmos Kirilovsky
Amos Kirilovsky
MEMarc Van Den Eynde
Marc Van Den Eynde
AMAna-Maria Mușină
Ana-Maria Mușină
MAMaria-Gabriela Anitei
Maria-Gabriela Anitei
FPFranck Pagès
Franck Pagès